AMDSeabelife SAS to develop next-gen dry AMD drugFrench drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy. more ➔
AmphiStar BVfinancingAmphiStar BV secures €6m to expand productionWaste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF). more ➔
HIVNaobios and Sumagen partner to develop HIV vaccineVaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate. more ➔
Industrial BiotechSolar Foods starts Factory01Finnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland. more ➔
ApprovalShock: Adrenomed AG gets FDA fast track designationGerman AdrenoMed AG has got FDA Fast Track designation for its targeted septic shock medicine enibarcimab that restores endothel integrity. more ➔
CollaborationLonza AG enters R&D collaboration with NeuroSense Therapeutics LtdALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration. more ➔
NeurologyLonza AG enters R&D collaboration with NeuroSense Therapeutics LtdALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration. more ➔
AcquisitionEssential Pharma acquires Renaissance Pharma LtdEssential Pharma has acquired Renaissance Pharma Ltd to commercialise the company’s Phase II program Hu14.18K322A in pedriatric high-risk neuroblastoma. more ➔
MalariaUnitaid awards Medincell US$6m to fight malariaGlobal health agency Unitaid has awarded French Medincell Corp (Jacou) an extension grant of up to US$ 6 million over three years to fund thesatety testing of its malaria vaccine mdc-STM. more ➔
FinancingGenmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBioGenmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline with … more ➔
AmphiStar BV
